[PDF][PDF] 治疗新型冠状病毒肺炎新药——莫努匹韦(molnupiravir) 胶囊
陈本川 - 医药导报, 2022 - yydbzz.com
2021 年11 月26 日, 世界卫生组织(WHO) 召开紧急会议向全世界通报, 一种令人担忧的新型
冠状病毒(SARS-CoV-2) 变异株正在世界各地传播, 各国亟需采取应对措施. WHO …
冠状病毒(SARS-CoV-2) 变异株正在世界各地传播, 各国亟需采取应对措施. WHO …
[PDF][PDF] 口服新型冠状病毒肺炎治疗新药——莫努匹韦
赵锦霞， 黄婧， 黄琳 - 临床药物治疗杂志, 2022 - lcywzlzz.com
莫努匹韦(molnupiravir) 是默克公司研发的口服抗新型冠状病毒肺炎新药, 是β-D-N4-
羟基胞苷(NHC) 的小分子核糖核苷前体药物, 其作用机制是干扰严重急性呼吸综合征冠状病毒2 …
羟基胞苷(NHC) 的小分子核糖核苷前体药物, 其作用机制是干扰严重急性呼吸综合征冠状病毒2 …
[PDF][PDF] 治疗新型冠状病毒肺炎新药——奈玛特韦(nirmatrelvir)片与利托那韦片组合用药Paxlovid®
陈本川 - 医药导报, 2022 - yydbzz.com
摘要自2019 年末新型冠状病毒肺炎(COVID-19) 暴发以来ꎬ 世界各国政府和科学工作者全力以
赴ꎬ 致力于开发各种防控疫苗, 生物制剂和化学治疗药物ꎬ 但随着新型冠状病毒(SARS-CoV-2) …
赴ꎬ 致力于开发各种防控疫苗, 生物制剂和化学治疗药物ꎬ 但随着新型冠状病毒(SARS-CoV-2) …
[HTML][HTML] Molnupiravir-An Oral Antiviral Drug for COVID-19
M Orders - Med Lett Drugs Ther, 2022 - medletter.com
The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was
granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of …
granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of …
[PDF][PDF] Safety and Effectiveness of Molnupiravir (LAGEVRIO Ò) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
MKAWY Yanagida, DKS Maekawa - 2023 - scienceopen.com
Introduction: Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
[HTML][HTML] Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
Y Liu, S Fan, A Xu, L Ge, X Wang, X Dong… - Frontiers in …, 2023 - frontiersin.org
Introduction: Randomized, controlled trials of molnupiravir in real-world use during the
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious diseases and …, 2023 - Springer
Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
Optimal dose and safety of the novel oral anti-viral molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of Antimicrobial …, 2021 - eprints.soton.ac.uk
Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
Y Liu, S Fan, A Xu, L Ge, X Wang, X Dong… - Frontiers in …, 2023 - frontiersin.org
Introduction: Randomized, controlled trials of molnupiravir in real-world use during the
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
Omicron wave are scarce. The frequency of hospitalization and death is low, so further …
Molnupiravir—a novel oral anti-SARS-CoV-2 agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …